

ZAMBIA – PENTAVALENT VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Zambia			
2. Grant Number: 0715-ZMB-04a-X			
3. Date of Decision Letter: 16 Decmeber 2014			
4. Date of the Partnership Framework Agreement: 22 October 2014			
5. Programme Title: New Vaccine Support			
6. Vaccine type: Pentavalent			
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 1 dose(s) per vial, LIQUID			
8. Programme Duration¹: 2005 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2005-2014	2015	Total ²
Programme Budget (US\$)	US\$50,754,137 ³	US\$3,943,500	US\$54,697,637
10. Vaccine Introduction Grant: n/a			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴			
Type of supplies to be purchased with Gavi funds in each year	2005-2014	2015	
Number of Pentavalent vaccines doses		1,936,200	
Number of AD syringes		2,034,700	
Number of safety boxes		22,400	
Annual Amounts (US\$)	US\$50,754,137 ⁵	US\$3,943,500	
12. Procurement agency: UNICEF			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

⁵ This is the consolidated amount for all previously approved years.

13. Self-procurement: n/a													
<p>14. Co-financing obligations: Reference code: 0715-ZMB-04a-X-C According to the Co-Financing Policy, the Country falls within the group Intermediate.</p> <p>The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <tr> <td>Type of supplies to be purchased with Country funds in each year</td> <td>2015</td> </tr> <tr> <td>Number of vaccine doses</td> <td>334,500</td> </tr> <tr> <td>Number of AD syringes</td> <td>351,500</td> </tr> <tr> <td>Number of safety boxes</td> <td>3,875</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$639,821</td> </tr> <tr> <td>Total Co-Financing Payments (US\$) (including freight)</td> <td>US\$681,500</td> </tr> </table>		Type of supplies to be purchased with Country funds in each year	2015	Number of vaccine doses	334,500	Number of AD syringes	351,500	Number of safety boxes	3,875	Value of vaccine doses (US\$)	US\$639,821	Total Co-Financing Payments (US\$) (including freight)	US\$681,500
Type of supplies to be purchased with Country funds in each year	2015												
Number of vaccine doses	334,500												
Number of AD syringes	351,500												
Number of safety boxes	3,875												
Value of vaccine doses (US\$)	US\$639,821												
Total Co-Financing Payments (US\$) (including freight)	US\$681,500												
15. Operational support for campaigns: Not applicable													
<p>16. Additional documents to be delivered for future disbursements:</p> <table border="1"> <tr> <td>Reports, documents and other deliverables</td> <td>Due dates</td> </tr> <tr> <td>Annual Progress Report or its equivalent</td> <td>15 May 2015</td> </tr> </table>		Reports, documents and other deliverables	Due dates	Annual Progress Report or its equivalent	15 May 2015								
Reports, documents and other deliverables	Due dates												
Annual Progress Report or its equivalent	15 May 2015												
17. Financial Clarifications: n/a													
18. Other conditions: n/a													

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
16 December 2014

ZAMBIA – PNEUMOCOCCAL VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Zambia			
2. Grant Number: 1215-ZMB-12b-X			
3. Date of Decision Letter: 16 December 2014			
4. Date of the Partnership Framework Agreement: 22 October 2014			
5. Programme Title: New Vaccine Support			
6. Vaccine type: Pneumococcal			
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV10), 2 dose(s) per vial , LIQUID			
8. Programme Duration¹: 2012 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2012-2014	2015	Total ²
Programme Budget (US\$)	US\$19,948,843 ³	US\$8,844,500	US\$28,793,343
10. Vaccine Introduction Grant: n/a			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴			
Type of supplies to be purchased with Gavi funds in each year	2012-2014	2015	
Number of Pneumococcal vaccines doses		2,136,800	
Number of AD syringes		2,244,800	
Number of safety boxes		24,725	
Annual Amounts (US\$)	US\$19,948,843 ⁵	US\$8,844,500	
12. Procurement agency: UNICEF			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

⁵ This is the consolidated amount for all previously approved years.

13. Self-procurement: n/a													
<p>14. Co-financing obligations: Reference code: 1215-ZMB-12b-X-C According to the Co-Financing Policy, the Country falls within the group Intermediate.</p> <p>The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p> <table border="1"> <thead> <tr> <th>Type of supplies to be purchased with Country funds in each year</th> <th>2015</th> </tr> </thead> <tbody> <tr> <td>Number of vaccine doses</td> <td>198,400</td> </tr> <tr> <td>Number of AD syringes</td> <td>208,400</td> </tr> <tr> <td>Number of safety boxes</td> <td>2,300</td> </tr> <tr> <td>Value of vaccine doses (US\$)</td> <td>US\$669,092</td> </tr> <tr> <td>Total Co-Financing Payments (US\$) (including freight)</td> <td>US\$701,000</td> </tr> </tbody> </table>		Type of supplies to be purchased with Country funds in each year	2015	Number of vaccine doses	198,400	Number of AD syringes	208,400	Number of safety boxes	2,300	Value of vaccine doses (US\$)	US\$669,092	Total Co-Financing Payments (US\$) (including freight)	US\$701,000
Type of supplies to be purchased with Country funds in each year	2015												
Number of vaccine doses	198,400												
Number of AD syringes	208,400												
Number of safety boxes	2,300												
Value of vaccine doses (US\$)	US\$669,092												
Total Co-Financing Payments (US\$) (including freight)	US\$701,000												
15. Operational support for campaigns: n/a													
<p>16. Additional documents to be delivered for future disbursements:</p> <table border="1"> <thead> <tr> <th>Reports, documents and other deliverables</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>Annual Progress Report or its equivalent</td> <td>15 May 2015</td> </tr> </tbody> </table>		Reports, documents and other deliverables	Due dates	Annual Progress Report or its equivalent	15 May 2015								
Reports, documents and other deliverables	Due dates												
Annual Progress Report or its equivalent	15 May 2015												
17. Financial Clarifications: n/a													
18. Other conditions: n/a													

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
16 December 2014

ZAMBIA – ROTAVIRUS VACCINE SUPPORT

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Zambia			
2. Grant Number: 1315-ZMB-13b-X			
3. Date of Decision Letter: 16 December 2014			
4. Date of the Partnership Framework Agreement: 22 October 2014			
5. Programme Title: New Vaccine Support			
6. Vaccine type: Rotavirus			
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 dose(s) schedule			
8. Programme Duration¹: 2013 - 2015			
9. Programme Budget (indicative) (subject to the terms of the Partnership Framework Agreement):			
	2013-2014	2015	Total ²
Programme Budget (US\$)	US\$3,894,148 ³	US\$3,678,000	US\$7,572,148
10. Vaccine Introduction Grant: n/a			
11. Indicative Annual Amounts (subject to the terms of the Partnership Framework Agreement):⁴			
Type of supplies to be purchased with Gavi funds in each year	2013-2014	2015	
Number of Rotavirus vaccines doses		1,381,500	
Annual Amounts (US\$)	US\$3,894,148 ⁵	US\$3,678,000	
12. Procurement agency: UNICEF			
13. Self-procurement: n/a			

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the consolidated amount for all previous years.

⁴ This is the amount that Gavi has approved. Please amend the indicative Annual Amounts from previous years if that changes subsequently.

⁵ This is the consolidated amount for all previously approved years.

14. Co-financing obligations: Reference code: 1315-ZMB-13b-X-C

According to the Co-Financing Policy, the Country falls within the group Intermediate.

The following table summarises the Co-Financing Payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2015
Number of vaccine doses	150,000
Value of vaccine doses (US\$)	US\$383,228
Total Co-Financing Payments (US\$) (including freight)	US\$398,500

15. Operational support for campaigns: n/a

16. Additional documents to be delivered for future disbursements:

Reports, documents and other deliverables	Due dates
Annual Progress Report or its equivalent	15 May 2015

17. Financial Clarifications: n/a

18. Other conditions: n/a

Signed by,



On behalf of Gavi
Hind Khatib-Othman
Managing Director, Country Programmes
16 December 2014